Stock TMDX TRANSMEDICS GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TransMedics Group, Inc.

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
128 USD +2.85% Intraday chart for TransMedics Group, Inc. +39.00% +62.16%
05-03 Transmedics Group Insider Sold Shares Worth $7,986,219, According to a Recent SEC Filing MT
05-03 Transmedics Group Insider Sold Shares Worth $1,600,633, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 402.3 540.5 532 1,970 2,577 4,205 - -
Enterprise Value (EV) 1 355.8 449.5 474.8 1,828 2,688 4,400 4,384 4,127
P/E ratio -8.06 x -17.2 x -12 x -50.2 x -103 x 130 x 83.8 x 53.7 x
Yield - - - - - - - -
Capitalization / Revenue 17 x 21.1 x 17.6 x 21.1 x 10.7 x 10.5 x 8.04 x 6.52 x
EV / Revenue 15.1 x 17.5 x 15.7 x 19.6 x 11.1 x 11 x 8.38 x 6.4 x
EV / EBITDA -12.5 x -18.1 x -12.6 x -65.4 x -131 x 62.1 x 38.3 x 25.9 x
EV / FCF -11 x -14.6 x -14.7 x -31.7 x -16.3 x -33.8 x 46.6 x 26 x
FCF Yield -9.12% -6.83% -6.82% -3.16% -6.13% -2.95% 2.14% 3.85%
Price to Book 7.37 x 4.73 x 7.85 x 10.6 x 18.8 x 20.1 x 15.1 x 9.91 x
Nbr of stocks (in thousands) 21,164 27,161 27,768 31,924 32,648 32,851 - -
Reference price 2 19.01 19.90 19.16 61.72 78.93 128.0 128.0 128.0
Announcement Date 17/03/20 02/03/21 23/02/22 22/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 23.6 25.64 30.26 93.46 241.6 401.5 523.1 645.3
EBITDA 1 -28.38 -24.81 -37.61 -27.96 -20.55 70.85 114.3 159.5
EBIT 1 -29.6 -26.38 -39.43 -31.44 -28.73 40.47 65.42 111
Operating Margin -125.42% -102.91% -130.29% -33.64% -11.89% 10.08% 12.51% 17.2%
Earnings before Tax (EBT) 1 -33.51 -28.72 -44.18 -36.16 -26.67 38.91 67.45 104.2
Net income 1 -33.55 -28.75 -44.22 -36.23 -25.03 34.53 54.6 86.69
Net margin -142.12% -112.13% -146.11% -38.77% -10.36% 8.6% 10.44% 13.44%
EPS 2 -2.360 -1.160 -1.600 -1.230 -0.7700 0.9858 1.527 2.383
Free Cash Flow 1 -32.45 -30.72 -32.38 -57.72 -164.9 -130 94 159
FCF margin -137.48% -119.82% -107.01% -61.76% -68.24% -32.38% 17.97% 24.64%
FCF Conversion (EBITDA) - - - - - - 82.21% 99.67%
FCF Conversion (Net income) - - - - - - 172.17% 183.4%
Dividend per Share - - - - - - - -
Announcement Date 17/03/20 02/03/21 23/02/22 22/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 5.37 9.668 15.88 20.52 25.68 31.38 41.55 52.46 66.43 81.17 96.85 98.96 101.7 104.3 119.6
EBITDA 1 -11.27 -10.86 -8.862 -8.95 -4.653 -5.494 3.119 5.444 0.77 6.208 11.1 13.1 17.55 20.1 0.8
EBIT 1 -11.72 -11.33 -9.369 -9.745 -5.544 -6.779 -2.089 -0.906 -1.123 2.603 12.42 8.291 10.12 8.908 17.08
Operating Margin -218.34% -117.17% -59% -47.49% -21.59% -21.61% -5.03% -1.73% -1.69% 3.21% 12.82% 8.38% 9.95% 8.54% 14.28%
Earnings before Tax (EBT) 1 -12.95 -12.65 -10.56 -11.5 -7.407 -6.701 -2.625 -0.98 -26.93 3.863 12.39 6.988 9.128 9.312 16.58
Net income 1 -12.96 -12.67 -10.56 -11.52 -7.426 -6.72 -2.636 -1.001 -25.42 4.031 12.2 6.025 7.282 7.166 16.6
Net margin -241.38% -131.03% -66.51% -56.15% -28.91% -21.42% -6.34% -1.91% -38.27% 4.97% 12.59% 6.09% 7.16% 6.87% 13.88%
EPS 2 -0.4700 -0.4600 -0.3800 -0.4100 -0.2500 -0.2100 -0.0800 -0.0300 -0.7800 0.1200 0.3500 0.2260 0.2192 0.1793 0.4100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 09/11/21 23/02/22 03/05/22 01/08/22 03/11/22 22/02/23 01/05/23 03/08/23 06/11/23 26/02/24 30/04/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 111 195 180 -
Net Cash position 1 46.5 91 57.3 142 - - - 77.5
Leverage (Debt/EBITDA) - - - - -5.421 x 2.758 x 1.571 x -
Free Cash Flow 1 -32.5 -30.7 -32.4 -57.7 -165 -130 94 159
ROE (net income / shareholders' equity) -137% -36.3% -51.5% -28.4% -15.4% 18.1% 17.5% 22.3%
ROA (Net income/ Total Assets) -45.5% -22.3% -30.8% -17.6% -5.09% 4.28% 6.14% 9.24%
Assets 1 73.73 128.7 143.5 206 491.6 807.2 889.5 937.9
Book Value Per Share 2 2.580 4.210 2.440 5.830 4.200 6.380 8.490 12.90
Cash Flow per Share 2 - - - - -0.4000 0.2700 -0.2500 -
Capex 1 0.17 0.46 3.52 11.9 152 105 21 22
Capex / Sales 0.7% 1.77% 11.63% 12.74% 62.84% 26.15% 4.01% 3.41%
Announcement Date 17/03/20 02/03/21 23/02/22 22/02/23 26/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for TransMedics Group, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
128 USD
Average target price
120.5 USD
Spread / Average Target
-5.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
TRANSMEDICS GROUP, INC. Stock TransMedics Group, Inc.
+62.16% 4.2B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.84% 218B
DANAHER CORPORATION Stock Danaher Corporation
+7.35% 184B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+13.04% 135B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.03% 107B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-1.33% 62.38B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.9B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+0.30% 40.87B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+2.78% 36.28B
RESMED, INC. Stock ResMed, Inc.
+26.14% 31.88B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. TMDX Stock
  4. Financials TransMedics Group, Inc.